NIOX
- Company typePublic
- Founded1998
- HeadquartersOxford, United Kingdom
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
NIOX firmographics
Firmographics- Name
- NIOX
- Legal name
- NIOX Group plc
- Website
- https://niox.com
- Company type
- Public
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
NIOX industry classification
Industry- Product category
- Respiratory Diagnostic Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate) (HLAHAGAI)
- akta.pro secondary industry
- Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry) (HLAHACAD)
Keywords
Where NIOX is headquartered
LocationHeadquarters
- HQ city
- Oxford
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
NIOX business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Others
Revenue model
- Clinical FeNO Testing: Primary revenue stream from clinical FeNO testing devices and sensors. H1 2026 clinical revenue grew to £20.6m from £20.0m, representing strategic prioritization of the clinical business over research operations.
- Research FeNO Testing: Revenue from research sector FeNO testing declined to £3.4m following strategic shift to prioritize clinical business inventory allocation. Represents historical strength in research market with device of choice in thousands of clinical trials globally.
- Sensor Supply Agreement: 10-year exclusive sensor supply agreement secured, providing long-term recurring sensor revenue stream from replacement sensors for installed device base.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | NIOX VERO device and sensors - pricing by quote |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels7 records
NIOX product offering
Product offeringCore offering
NIOX manufactures and sells handheld electrochemical medical devices that measure fractional exhaled nitric oxide (FeNO) at the point of care to support the diagnosis and management of asthma. The NIOX VERO and NIOX PRO devices are sold primarily to healthcare professionals in primary care, secondary care, research, and pharmacy settings, with recurring revenue from replacement sensors under a 10-year exclusive supply agreement.
Product overview
NIOX Group plc is a medical technology company specializing in respiratory diagnostics, specifically fractional exhaled nitric oxide (FeNO) testing for asthma diagnosis and management. The company pioneered FeNO testing in 1998 and offers a portfolio of handheld electrochemical FeNO testing devices, software platforms, and educational tools. The core product is the NIOX VERO® handheld device for point-of-care FeNO measurement, complemented by the NIOX PRO® clinical device (CE Mark and UK MHRA approved in 2026), NIOX Cloud™ data management platform, and the FeNO Learn educational app. Additional offerings include the nioxOS® operating system, patient-facing FeNO for Me portal, augmented reality demo tools, multilingual website translation via NIOX Lingua™, and extensive educational content including webinars, masterclasses, case studies, and a podcast series.
Differentiator
Problem solved
Functional benefit
Brands
- NIOX VERO: Gold standard FeNO testing device for measuring fractional exhaled nitric oxide in patients with asthma
- NIOX PRO
- FeNO Learn
- nioxOS
- NIOX Cloud
- NIOX Lingua
Products and services
- NIOX VERO® Flagship handheld electrochemical FeNO (fractional exhaled nitric oxide) testing device for point-of-care diagnosis and monitoring of asthma in primary and secondary care settings, with touchscreen interface and Flow Rate Control technology including child compatibility mode.
- NIOX PRO® Professional-grade FeNO testing device for clinical settings, expanding NIOX's clinical product portfolio alongside NIOX VERO. CE Mark and UK MHRA approved.
- NIOX Cloud™ Cloud-based data management and connectivity platform for NIOX devices, enabling data storage and remote monitoring of FeNO testing results.
- FeNO Learn Mobile application (iOS and Google Play) and web-based educational platform providing healthcare professionals with courses, webinars, case studies, masterclasses, and an interpreting FeNO tool to support FeNO testing education.
- NIOX Replacement Sensors Pre-calibrated electrochemical sensors for use with NIOX VERO and NIOX PRO devices, supplied under a 10-year exclusive sensor supply agreement as a recurring consumable revenue stream.
Quantifiable outcome
- 50% reduction in asthma exacerbations with FeNO-guided management during pregnancy
- +4 more outcomes
Companies that use NIOX
Customer profileNamed customers7 records
Segments4 records
Ideal customer profiles4 records
NIOX technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
NIOX partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor and flagship.
- ResMedminorResMed acquired BreathSmart in March 2025 to expand its digital therapeutics platform. Competitive context - ResMed is a major player in respiratory device market but no direct partnership with NIOX mentioned.
- Philips HealthcareminorPhilips collaboration with Oventus Medical (November 2024) in sleep and respiratory care. Competitive context - industry collaboration in respiratory device space.
- Wessex Academic Health Science Network (AHSN)flagshipPartnership with NHS England Accelerated Access Collaborative (AAC) Rapid Uptake Programme to improve patient outcomes through FeNO testing integration in primary care. Programme resulted in 58,000 new asthma diagnoses, 1,244 devices deployed in primary care, 53% of primary care networks gaining FeNO access, and nearly 5,000 hours of training completed. Supported by £915,000 AAC Pathway Transformation Fund across 33 projects.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
NIOX competitors and assessment
Company assessmentDirect peers
- Bedfont Scientific: Bedfont's NObreath is a handheld FeNO device used by clinicians for asthma assessment, making it the closest direct commercial competitor to NIOX VERO.
- Bosch Healthcare Solutions: Bosch's Vivatmo pro is an electrochemical FeNO testing system targeting the same primary care and specialist clinicians as NIOX, with comparable point-of-care workflow.
- Medisoft: Medisoft manufactures FeNO analyzers (HypAir FeNO) used in clinical and research respiratory diagnostics, overlapping directly with NIOX on technology and customer base.
- Eco Medics: Eco Medics builds chemiluminescence-based exhaled nitric oxide analyzers used as reference instruments against which NIOX sensors are calibrated, competing for the same respiratory research and clinical market.
- Aerocrine (Circassia): Aerocrine originally commercialised the NIOX technology and was acquired by Circassia; Circassia retains a respiratory diagnostics franchise competing in FeNO and adjacent airway inflammation testing.
Broad incumbents
- ResMed: Global leader in sleep and respiratory care that acquired BreathSmart in March 2025, signalling expansion into connected respiratory diagnostics adjacent to NIOX's point-of-care testing.
- Philips Healthcare: Broad respiratory and sleep portfolio including ventilators and connected care; its collaboration with Oventus Medical (November 2024) increases competitive pressure on niche players like NIOX.
- Pulmonx: Pulmonx provides interventional pulmonology diagnostics and serves the same hospital-based respiratory specialists that NIOX targets in secondary care for severe asthma assessment.
Emerging players
- MGC Diagnostics (Medical Graphics / Spirosure): MGC Diagnostics supplies pulmonary function and FeNO-related testing equipment, partially overlapping NIOX's offerings across respiratory diagnostics workflows.
Others
- AstraZeneca: Major biologic manufacturer in severe asthma (eosinophilic and Type 2 inflammation); NIOX's severe-asthma and biologic-selection use case is directly adjacent to AZ's commercial franchise, making AZ a strategic partner/competitor.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
NIOX social profiles
Digital presenceNIOX compliance and trust
Trust signalCompliance2 records
NIOX financial estimates
Financial estimateRevenue estimate
Valuation estimate
NIOX leadership team
Management profileNumber of profiles
Profiles4 records
NIOX subsidiaries and ownership
Company hierarchySubsidiaries1 record
NIOX funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NIOX M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NIOX
What does NIOX do?
NIOX manufactures and sells handheld electrochemical medical devices that measure fractional exhaled nitric oxide (FeNO) at the point of care to support the diagnosis and management of asthma. The NIOX VERO and NIOX PRO devices are sold primarily to healthcare professionals in primary care, secondary care, research, and pharmacy settings, with recurring revenue from replacement sensors under a 10-year exclusive supply agreement.
Is NIOX a public or private company?
NIOX is a public company. It is classified as public and is currently operating.
When was NIOX founded?
NIOX was founded in 1998. It employs 101 to 250 people.
Where is NIOX based?
NIOX is headquartered in Oxford, United Kingdom, in the Europe region.
How does NIOX make money?
Three revenue lines are on record. Clinical FeNO Testing is the primary driver. The others are research FeNO Testing and sensor Supply Agreement.
Who are NIOX's main competitors?
Direct peers on record are Bedfont Scientific, Bosch Healthcare Solutions, Medisoft, Eco Medics and Aerocrine (Circassia). Broad incumbents are ResMed, Philips Healthcare and Pulmonx. MGC Diagnostics (Medical Graphics / Spirosure) is listed as an emerging player. AstraZeneca is listed as an others.
Does NIOX have an API?
No public API is recorded for NIOX.
What industry is NIOX in?
NIOX's product category is Respiratory Diagnostic Devices. Its primary akta.pro industry code is HLAHAGAI, Respiratory Monitoring & Oximetry (Capnography, Pulse Oximeters, Respiratory Rate), with a secondary code of HLAHACAD, Blood Oxygen & Respiratory Monitoring (Pulse Oximetry, Capnography, Spirometry). Its NAICS code is 334510 and its SIC code is 3845.